Literature DB >> 11431376

The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1.

A Arvand1, S M Welford, M A Teitell, C T Denny.   

Abstract

More than 85% of Ewing's family tumors carry a specific chromosomal translocation that fuses the NH(2) terminus of the EWS gene to the COOH terminus of the FLI1 transcription factor. It has been shown previously that both the transactivation domain encoded by EWS and the DNA binding domain of FLI1 were necessary for transforming cells to anchorage independence. We now report that a COOH-terminal domain in addition to the FLI1 DNA binding domain is necessary to promote cellular transformation. NIH 3T3 cells expressing a COOH-terminal deletion mutant (EWS/FLI1 DeltaC) have a greatly reduced capability to form colonies in soft agar and tumors in severe combined immunodeficient mice. The rate of tumor formation for NIH 3T3 that express EWS/FLI1 DeltaC is 50 days, whereas EWS/FLI1 forms tumors within 22 days. In addition, cells expressing the EWS/FLI1 DeltaC mutant failed to completely demonstrate the round-cell histology that is seen in both Ewing's tumor cell lines and NIH 3T3 cells expressing full-length EWS/FLI1. Northern and microarray analyses were performed to assess the effect of loss of the FLI1 COOH terminus on transcriptional modulation of EWS/FLI1 target genes. We found that although EWS/FLI1 DeltaC up-regulates smaller numbers of genes (21 genes) compared with EWS/FLI1 (34 genes), 41% of the EWS/FLI1 targets were also up-regulated by EWS/FLI1 DeltaC. On the other hand, EWS/FLI1 DeltaC is unable to down-regulate genes (3 genes) as efficiently as EWS/FLI1 (39 genes) with only one target gene repressed by both fusion constructs. Our study indicates that the EWS/FLI1 transcription factor has strong transcriptional activating as well as repressing properties and suggests that transcriptional activation and repression of target genes may occur through biochemically different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1.

Authors:  Omar Moussa; Amanda C LaRue; Romeo S Abangan; Christopher R Williams; Xian K Zhang; Masahiro Masuya; Yong Z Gong; Demetri D Spyropoulos; Makio Ogawa; Gary Gilkeson; Dennis K Watson
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

Review 2.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

3.  Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins.

Authors:  Sungeun Kim; Christopher T Denny; Ron Wisdom
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 4.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

5.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.

Authors:  Günther H S Richter; Stephanie Plehm; Annette Fasan; Sabine Rössler; Rebekka Unland; Idriss M Bennani-Baiti; Marc Hotfilder; Diana Löwel; Irene von Luettichau; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Heinrich Kovar; Martin S Staege; Carsten Müller-Tidow; Stefan Burdach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

Review 6.  Molecular genetics of pediatric soft tissue tumors: clinical application.

Authors:  Chung-Che Chang; Vinod B Shidham
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

7.  Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin.

Authors:  Yoshihide Asano; Margaret Markiewicz; Masahide Kubo; Gabor Szalai; Dennis K Watson; Maria Trojanowska
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

8.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

Review 9.  The potential for molecular therapeutic targets in Ewing's sarcoma.

Authors:  Nancy R McAllister; Stephen L Lessnick
Journal:  Curr Treat Options Oncol       Date:  2005-11

10.  The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma.

Authors:  Megann A Boone; Cenny Taslim; Jesse C Crow; Julia Selich-Anderson; Andrea K Byrum; Iftekhar A Showpnil; Benjamin D Sunkel; Meng Wang; Benjamin Z Stanton; Emily R Theisen; Stephen L Lessnick
Journal:  Oncogene       Date:  2021-06-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.